April 15, 2025
November 18, 2024
December 12, 2023
November 6, 2023
October 10, 2023
June 30, 2023
Toragen, Inc. Announces FDA Acceptance of IND Application for TGN-S11 for the Treatment of HPV-Induced Cancers
February 28, 2023
Toragen, Inc. Announces Appointment of Chief Scientific Officer
February 08, 2023
Toragen, Inc. Announces Chief Medical Officer to Drive the Company’s Clinical Development
October 7, 2022
Toragen, Inc. Announces Raising $5.4M in a Series Seed Round
September 30, 2022
Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff
August 15, 2022
Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO
February 09, 2022
A: Toragen was incorporated in 2016 in Delaware
A: Toragen’s headquarters and mailing address are at Toragen, Inc. 9276 Scranton Rd., #500, San Diego, CA 92121.
A: Toragen is currently developing therapeutics for the treatment of HPV-induced cancers. More information can be found here.
Investing And Stock
A: Toragen’s stock is currently private and not available for purchase through a stock exchange. If you wish to invest in Toragen please contact ir@toragen.com.
A: Unfortunately, Toragen cannot offer investment advice with regard to your current or future investment. Please contact your tax professional or financial advisor.
A: Please contact ir@toragen.com should you need access to your documents.
A: Updates are typically sent quarterly via email. Please inform us immediately if you are not receiving these updates or would like to change your email address.
Accounting and Accounts Payable: ap@toragen.com
Investor Relations: ir@toragen.com
Careers: careers@toragen.com
HR: hr@toragen.com
General: inquiries@toragen.com
9276 Scranton Rd. Suite 500, San Diego, California 92121, United States
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.